Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration Clinical Trial

Official title:

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03290794
• Other study ID #: 19140
• Status: Completed
• Start date: February 14, 2019
• Est. completion date: May 26, 2023

Study information

• Verified date: June 2023
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The proposed regulatory post-marketing surveillance (PMS) study will be planned to collect the safety data of aflibercept intravitreal injection in patients with wet Age-related Macular Degeneration (AMD) in real-life treatment practice

The primary objective is:

• To collect safety data in wet AMD patients treated with intravitreal aflibercept injection

The secondary objective is:

• To determine how disease activity is monitored including type and frequency of ocular tests and frequency of injections

Description:

The study will be multicenter, observational, prospective, single arm, post marketing surveillance study of intravitreal aflibercept injection in wet AMD patients in routine clinical practice and real-life conditions without any protocol mandated interventions.

Approximately 100 wet AMD patients from up to ten ophthalmology clinics across India will be enrolled in this study. Each study site will be requested to enroll approximately 10 patients, however, the sites will be asked to enrolled additional patients in case of failure to enroll 10 patients by other site to complete the recruitment of approximately 100 patients.

Patients will be observed for maximum period of 6 months after the start of intravitreal aflibercept treatment. The observation period should cover the entire period from initial visit to the last follow-up visit at six months or withdrawal of consent, or the patient is lost to follow up (whatever is earliest).

The study site will be asked to enroll into the study all consecutive patients with wet AMD for whom the decision has been made to treat with intravitreal aflibercept injection and patients agrees to sign informed consent form for data collection purpose.

Any switch to another therapy or initiated administration of other anti-VEGF (Vascular Endothelial Growth Factor) injection in fellow eye or the discontinuation of treatment with IVT-AFL before the 6 month implies the end of the observation period. However, the safety follow-up will continue at least 30 days after last intravitreal aflibercept injection or in case of the discontinuation of treatment with IVT-AFL or till the patient switch the treatment from IVT-AFL and received other anti-VEGF injection before the 6 month observation period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 26, 2023
• Est. primary completion date: November 25, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Decision to treat with intravitreal aflibercept injection prior to patient enrolment as per the treating ophthalmologist's routine clinical practice.

• Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities (DCGI) for use with intravitreal aflibercept injection.

• Patient or legal delegate signed informed consent.

Exclusion Criteria:

• Participation in a clinical trial of an investigational agent within 30 days.

• Patients receiving other anti-VEGF agent in fellow eye.

• Contraindications according to the local prescribing information.

Related Conditions & MeSH terms

• Macular Degeneration
• Wet Age-related Macular Degeneration

Intervention

Drug:
• Aflibercept (Eylea, BAY86-5321)
Intravitreal Aflibercept as prescribed by the treating Physician

Locations

Country	Name	City	State
India	Many Locations	Multiple Locations

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of reported ocular and non-ocular adverse events during observation period	unilateral / bilateral treatment	Up to 6 months
Primary	Percentage of reported ocular and non-ocular adverse events during observation period	unilateral / bilateral treatment	Up to 6 months
Secondary	Type of ocular tests undertaken	e.g. Visual acuity, ocular computed tomography, indocyanine angiography, Angiography, Fundus photography	Up to 6 months
Secondary	Interval between ocular test	Date of ocular test	Up to 6 months
Secondary	Date of aflibercept injections	Date of aflibercept injections	Up to 6 months
Secondary	Injection dose	Injection dose	Up to 6 months
Secondary	Interval (days) between aflibercept injections	During observation periods	Up to 6 months
Secondary	Frequency of monitoring / clinic visits	Frequency of monitoring / clinic visits	Up to 6 months

External Links

•   Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.